Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

SNDL Inc SNDL

SNDL Inc. is a Canada-based private-sector liquor and cannabis retailer in Canada with retail banners, which include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, Spiritleaf, and Firesale Cannabis. Its segments include Liquor Retail, Cannabis Retail, Cannabis Operations and Investments. The Liquor Retail segment includes the sale of wines, beers and spirits through liquor stores. The Cannabis Retail segment includes the private sale of recreational cannabis through and franchise retail cannabis stores. The Cannabis Operations segment includes the cultivation, distribution and sale of cannabis for the adult-use and medical markets domestically and for export, and providing cannabis processing services, in addition to product development, manufacturing, and commercialization of cannabis consumer packaged goods. The Investments segment includes the deployment of capital to investment opportunities. Its cannabis brand portfolio includes Top Leaf, Vacay, Grasslands and others.


NDAQ:SNDL - Post by User

<< Previous
Bullboard Posts
Next >>
Post by Kenchueon Jun 03, 2022 4:21am
82 Views
Post# 34728698

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance



FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance
 
FSD Pharma Inc CEO Anthony Durkacz told Proactive that the company is ready to proceed with the planned Phase 2 clinical trial of its FSD-201 drug candidate as soon as it gets the go-ahead from the US Food and Drug Administration and Health Canada. That's after submitting Investigational New Drug (IND) applications to the two bodies this week. Armed with cash of about $50 million following the $16.4 million disposal of its former cannabis production facility in Ontario, Durkacz said FSD is also moving full-steam ahead on its two other drug candidates and may look for other opportunities. A special dividend may also be on the cards, he added.



<< Previous
Bullboard Posts
Next >>